For Research Use Only. Not for Human or Veterinary Use.
Overview
Tirzepatide (development code LY3298176) is a synthetic linear peptide that activates two incretin receptors at once — the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is the first-in-class unimolecular GIP/GLP-1 dual agonist and one of the most heavily published compounds in metabolic research. A fatty-diacid chain on a PEG linker lets it bind albumin, which stretches its half-life to about five days and supports once-weekly dosing in study protocols.
🧪Chemical Profile
Property
Value
CAS number
2023788-19-2
Development code
LY3298176
Class
GIP / GLP-1 dual receptor agonist
Backbone
39-amino-acid linear peptide with a C20 fatty-diacid moiety on a PEG linker
Molecular formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight
4813.45 g/mol
Purity (HPLC)
≥ 98%
Appearance
White to off-white lyophilized powder
Tirzepatide at a glance
Class
GIP / GLP-1 dual agonist
Originator
Eli Lilly and Company
Research status
Extensive published literature
Study route
Subcutaneous, once weekly
Half-life
≈ 5 days
Key feature
First-in-class dual incretin agonist
🔬Mechanism of Action
Tirzepatide engineers a single molecule to switch on two class-B G-protein-coupled receptors, GIPR and GLP-1R. Both couple through Gαs to raise intracellular cAMP, which drives the downstream signalling associated with incretin action. The fatty-diacid/PEG modification is not a signalling element — it binds albumin to slow clearance.
Component
Detail
Primary targets
GIP receptor (GIPR) and GLP-1 receptor (GLP-1R)
Receptor class
Class B G-protein-coupled receptors
G-protein coupling
Gαs → adenylyl cyclase → cAMP
Downstream signalling
PKA, EPAC, CREB, PI3K/Akt pathways
β-arrestin
Recruited — linked to receptor desensitization and internalization
Physiologic effects studied in the literature (research context, not clinical claims):
Effect
Studied mechanism
Glucose-dependent insulin secretion
GLP-1R activation in pancreatic β-cells
Glucagon suppression
GLP-1R activation in pancreatic α-cells
Delayed gastric emptying
Vagal modulation via GLP-1R
Increased satiety
GLP-1R and GIPR activation in the hypothalamus
Energy expenditure / lipid handling
GIPR activation in adipose tissue
💊Pharmacology
Parameter
Value
Half-life (t½)
≈ 5 days (~113–119 h)
Time to peak (Tmax)
8–24 h post-dose
Bioavailability (SC)
≈ 80%
Volume of distribution
≈ 0.3 L/kg
Protein binding
≈ 99% (albumin)
Metabolism
Proteolytic degradation (no CYP involvement)
Elimination
Renal (peptide fragments) and fecal
📚Research Evidence
Tirzepatide has a large preclinical and clinical literature. The tables below name representative studies and trial programs and what they investigated; specific numerical outcomes are not restated here as claims.
Preclinical model
Research focus
Reference
Diet-induced obese mice
Body-weight and metabolic effects vs selective GLP-1 agonism
Coskun T, et al. (2018)
High-fat-diet mice
Glucose tolerance and lipid metabolism
Samms RJ, et al. (2020)
Receptor pharmacology
Biased / imbalanced dual GIP/GLP-1 agonism
Willard FS, et al. (2020)
Non-human primates
Dose-dependent body-composition effects
Urva S, et al. (2020)
Clinical program
Phase
Research focus
Reference
SURPASS-1 … 4
Phase 3
Glycemic control in type-2-diabetes study populations
Coskun T, et al. (2018)
SURPASS-2
Phase 3
Head-to-head vs semaglutide
Frías JP, et al. (2021), Lancet
SURMOUNT-1 / 2
Phase 3
Body-weight endpoints in obesity research
Jastreboff AM, et al. (2022), NEJM
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
Reported direction / finding
Context
Reference
Greater HbA1c reduction than semaglutide (head-to-head)
SURPASS-2, type-2-diabetes
Frías JP et al., Lancet 2021
Substantial body-weight reduction in obesity
SURMOUNT-1
Jastreboff AM et al., NEJM 2022
Dual GIP/GLP-1 exceeds selective GLP-1 in preclinical weight models
diet-induced obese mice
Coskun T et al., 2018
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
⚗️Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
Parameter
Reference value
Research dosing range (literature)
0.25–2.0 mg, once weekly (SC), in study protocols
Reconstitution solvent
Bacteriostatic water (0.9% benzyl alcohol)
Reconstitution volume
1–2 mL per vial
Final concentration
≈ 2.5–5 mg/mL
Storage (lyophilized)
−20°C, protected from light
Storage (reconstituted)
2–8°C, up to ~14 days
Do not use
If the solution is cloudy or contains particulates
🛡️Safety Profile
Published safety observations for the compound, provided as research reference only. This material is not for human or veterinary use.
Pancreatitis, gallbladder-related events reported at low frequency
Rodent finding
Thyroid C-cell tumors in rodent studies; human relevance unconfirmed
Interactions
Delayed gastric emptying may affect absorption of co-administered oral compounds
Status
For research use only; not for human or veterinary application
📐Physicochemical Properties
Property
Value
Physical state
White to off-white lyophilized powder
Solubility (water)
Freely soluble (> 50 mg/mL)
logP (octanol/water)
≈ 4.8
Isoelectric point (pI)
≈ 5.0
pH (reconstituted)
7.0–8.0
Appearance (solution)
Clear, colorless
Stability (lyophilized)
≥ 24 months at −20°C
🏭Synthesis & Manufacturing
Tirzepatide is assembled by solid-phase peptide synthesis, with the C20 fatty-diacid installed on a lysine side chain via a linker after selective side-chain deprotection. The long, highly charged sequence makes coupling efficiency and preparative purification the demanding steps.
Step
Detail
Strategy
Solid-phase peptide synthesis, Fmoc/tBu chemistry
Resin
Rink amide MBHA resin
Coupling
HATU / HBTU with DIPEA (double couplings for hindered residues)
Fatty-acid conjugation
C20 diacid coupled to a Lys side chain after selective (Mtt) deprotection
Lyophilization from dilute HCl (acetate → chloride)
Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
Critical quality attributes: correct molecular weight and low deletion-peptide content. A large, highly charged peptide — deletion-peptide control is important.
🔎Analytical Methods
Method
Parameter
Typical result
RP-HPLC (C18, UV 214 nm)
Purity
≥ 98%
HPLC retention
C18, 20–60% B over 25 min
Single main peak
ESI-MS (positive mode)
Identity / mass
[M+H]⁺ ≈ 4814 Da (multiply charged +4 to +8)
MALDI-TOF
Mass confirmation
[M+H]⁺ ≈ 4814 Da (multiply charged +4 to +8)
Amino-acid analysis
Composition
Consistent with the stated sequence
LC-MS (extracted ion)
Deletion-peptide impurities
Within specification
Karl Fischer
Water content
< 6%
LAL assay
Endotoxin
Within specification
Ion chromatography
Residual TFA
< 500 ppm
Representative RP-HPLC purity method:
Column: C18, 5 µm, 250 × 4.6 mm
Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
Gradient: 20–60% B over 25 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 4814 Da (multiply charged +4 to +8)). A large, highly charged peptide — deletion-peptide control is important.
📈Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
Condition
Duration
Result
Lyophilized, −20°C, dark
≥ 24 months
No significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark
≥ 12 months
Minimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)
3 months
< 5% degradation
Reconstituted, 2–8°C, dark
7–14 days
Minor degradation
Reconstituted, 25°C
24–48 h
Use promptly
Light exposure (ICH Q1B)
1.2 M lux·h
Generally light-stable
Freeze–thaw (−20°C ⇄ 25°C)
3 cycles
Acceptable — aliquot to avoid repeats
Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
Minimise freeze-thaw cycles; aliquot material used across many sessions.
Key factor: A large, highly charged peptide — deletion-peptide control is important.
📖Selected References
Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist: from discovery to clinical proof of concept. Diabetes, 2018.
Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. Journal of Biological Chemistry, 2020.
Frías JP, et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes (SURPASS-2). The Lancet, 2021.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
✅Quality & Supply
HPLC ≥ 98% purity with a Certificate of Analysis per batch
Identity confirmed by LC-MS; endotoxin tested by LAL
Research samples through to bulk, with worldwide delivery